<DOC>
	<DOCNO>NCT02532192</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose belinostat combine standard chemotherapy drug ( rituximab , cisplatin , cytarabine , dexamethasone ) patient relapse refractory DLBCL eligible autologous stem cell transplant ( transplant patient 's stem cell ) . The safety study drug also study .</brief_summary>
	<brief_title>A Phase Ib Study Belinostat With RDHAP Chemotherapy ( Dexamethasone , Cytarabine , Cisplatinum ) Adults With Relapsed Refractory Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>Study Groups : If participant find eligible take part study , assign dose level belinostat base join study . Up 4 dose level belinostat test . Between 3-6 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose belinostat find . All participant receive dose level standard chemotherapy drug . Study Drug Administration : Participant receive belinostat standard chemotherapy two 21-day cycle . Participant receive belinostat vein Days 1 2 cycle . The infusion last 24 hour . Participant receive rituximab cisplatin vein Day 2 cycle . Participant receive cytarabine vein Day 2 3 cycle , depend join study . Rituximab give 4-5 hour , cisplatin give 3-4 hour , cytarabine give 1 hour . Participant take dexamethasone day mouth Days 2-5 study cycle . Blood ( 5 tablespoon ) bone marrow collect 10 business day ( Monday-Friday ) participant begin receive belinostat . The blood bone marrow use peripheral blood mononuclear cell ( PBMC ) test . This testing design learn participant respond treatment . To collect bone marrow biopsy , area hip site numb anesthetic , small amount bone marrow withdrawn large needle . Participant also receive filgrastim , pegfilgrastim , SMX , valacyclovir , ciprofloxacin fluconazole reduce side effect . Participant 's study doctor discus take drug . If participant 's doctor think necessary , also bone marrow biopsy aspirate perform check status disease within 4 week begin receive belinostat . To collect bone marrow biopsy/aspirate , area hip site numb anesthetic , small amount bone marrow bone withdrawn large needle . Study Visits : Within 5 working/business day start cycle : - Participant physical exam . - Blood ( 4-6 tablespoon ) draw routine test . One ( 1 ) time week completion therapy cycle , blood ( 4-6 tablespoon ) draw routine test . Blood ( 4 tablespoon ) draw Days 1,2 , 3 , 21 ( +/- 72 hour ) Cycles 1 2 PBMC test . Length Treatment : Participant may continue take belinostat combine chemotherapy 3 cycle . Participant longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Patient 's participation study follow-up visit . End-of-Dosing Visit : Within 3 week start last cycle : - Participant physical exam . - Blood ( 4-6 tablespoon ) draw routine PBMC testing . - Participant FDG-PET/CT scan check status disease . - If participant 's doctor think necessary , may bone marrow biopsy aspirate check status disease - If participant 's doctor think necessary , may core needle biopsy check status disease . To perform core biopsy , sample tissue remove use hollow core needle cut edge . This investigational study . Belinostat FDA approve treat T-cell lymphoma . Its use study investigational . The standard chemotherapy drug commercially available FDA approve treat DLBCL . Up 40 participant enrol study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>1 . Aggressive Bcell lymphoma , include DLBCL FL indolent low grade malignancy transform DLBCL , Grade III FL , Burkitt lymphoma , unclassifiable Bcell lymphoma feature Burkitt DLBCL accord World Health Organization , biopsy confirmation disease relapse refractory standard cytotoxic chemotherapy combination include rituximab doxorubicin , autologous stem cell transplant plan . 2 . Have receive 1 2 prior cytotoxic treatment , include belinostat , RDHAP , autologous allogeneic stem cell transplant . Radiation preplanned occur conclusion systemic cytotoxic therapy consider separate prior therapy . Radiation administer potential recurrent relapse disease consider separate prior therapy . 3 . Patient durable power attorney ( DPA ) healthcare must able understand voluntarily sign IRBapproved inform consent form . 4 . Age 1880 year time signing informed consent . 5 . Patients must bidimensional measurable disease . 6 . Patients performance status &lt; /=3 ( Eastern Cooperative Oncology Group Performance Status Scale , 3 allow decline status deem related lymphoma felt potentially reversible treat physician ) . 7 . Within 4 week therapy start , serum bilirubin &lt; 1.5x ULN ( maximum level base MD Anderson laboratory range 1.95 mg/dL ) ; AST ( SGOT ) ALT ( SGPT ) &lt; /=3x ULN &lt; 5x ULN hepatic metastasis present ; ANC &gt; 1000/mm^3 platelet &gt; 100,000/mm^3 unless deem likely related lymphoma involvement bone marrow minimum ANC allowable 500/mm^3 minimum allowable platelet count 50,000/mm^3 . 8 . Within 4 week therapy start , renal function assess calculated creatinine clearance &gt; /= 50ml/min CockcroftGault formula use actual body weight . 9 . Patients must willing receive transfusion blood product . 10 . Within 4 week therapy start , woman childbearing potential must negative serum ( Betahuman chorionic gonadotropin [ BetahCG ] ) urine pregnancy test screening must adhere scheduled pregnancy test . 11 . Women childbearing potential men sexually active woman childbearing potential must practice highly effective method birth control study ( 12 month woman 3 month men ) , consistent local regulation regard use birth control method subject participate clinical study . 1 . Any serious medical condition include limited uncontrolled hypertension , uncontrolled diabetes mellitus , active/symptomatic coronary artery disease , COPD , leave ventricular ejection fraction less 40 , active infection , active hemorrhage , psychiatric illness , investigator opinion place patient unacceptable risk would prevent subject signing informed consent form . Patients history cardiac arrhythmia cardiac evaluation clearance . 2 . Pregnant lactating female . 3 . Known hypersensitivity component RDHAP . 4 . Patients Gilbert 's syndrome unless homozygosity UFT1A1*28 mutation exclude . 5 . HIV infection , active hepatitis B infection , active hepatitis C infection . 6 . Known homozygous UGT1A1*28 mutation prior test family history . 7 . Requirement therapy UGT1A1 Inhibitor , detailed Section 8.4 , use within 7 day enrollment protocol . 8 . All patient active central nervous system involvement lymphoma . 9 . Diagnosis prior malignancy within past 2 year exception successfully treat basal cell carcinoma , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast . History malignancy allow remission ( include prostate cancer patient remission radiation therapy , surgery brachytherapy ) , actively treat , life expectancy &gt; 3 year . 10 . Significant neuropathy ( Grades 3 4 , Grade 2 pain ) within 14 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Diffuse large B-cell lymphoma</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Belinostat</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Platinol-AQ</keyword>
	<keyword>Platinol</keyword>
	<keyword>CDDP</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Ciprofloxacin</keyword>
	<keyword>Ciprofloxacin hydrochloride</keyword>
	<keyword>Cipro</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Diflucan</keyword>
</DOC>